PMID- 26714421
OWN - NLM
STAT- MEDLINE
DCOM- 20160930
LR  - 20151230
IS  - 1735-367X (Electronic)
IS  - 1735-1383 (Linking)
VI  - 12
IP  - 4
DP  - 2015 Dec
TI  - Serum Levels of Monocyte Chemoattractant Protein-1 Correlate with Poor Clinical 
      Grades in Cerebral Aneurysms.
PG  - 302-10
AB  - BACKGROUND: Ruptured cerebral aneurysms (ICAs) are the most common non-traumatic 
      cause of subarachnoid hemorrhage (SAH) that is associated with life threatening 
      complications such as Vasospasm, Infarction, and Hydrocephalus (HCP). The active 
      participation of macrophage/monocyte-mediated inflammatory response in the 
      pathogenesis of cerebral aneurysm as labeled with Monocyte Chemoattractant 
      Protein-1 (MCP-1) is suggested. OBJECTIVE: To measure the serum level of MCP-1 in 
      ruptured CAs in different time intervals. METHODS: We measured the serum levels 
      of MCP-1 in SAH patients who had CAs and compared it with that of MCP-1 in two 
      control groups: including patients with SAH without CAs, and the normal 
      population of blood donors. We also measured the MCP-1 levels in patients with 
      CAs one week afterward to evaluate the effect of treatment. Serum level of MCP-1 
      was measured by a commercial ELISA assay. RESULTS: Mean serum MCP-1 level in 
      patients with SAH and CAs was 188.2168 Pg/ml and 331.3982 Pg/ml in the normal 
      population. There was no statistically significant difference between serum 
      levels of MCP-1 on the first (mean=188.2168 Pg/ml) and 7th days after SAH onset 
      (mean=171.8450 Pg/ml) (p=0.739). Serum level of MCP-1 increased significantly as 
      Glasgow Coma Scale decreased (p=0.078) and Hunt and Hess score increased 
      (p=0.089). CONCLUSION: Our results did not show an increasing MCP-1 serum level 
      in patients with aneurysmal SAH. There was a relationship between poor clinical 
      grade and MCP-1 levels in patients with CAs. MCP-1 may be a local inflammatory 
      marker for cerebral aneurysms without systemic manifestation.
FAU - Rahmanian, Abdolkarim
AU  - Rahmanian A
AD  - Department of Neurosurgery, Shiraz Medical School, Shiraz University of Medical 
      Sciences, Shiraz, Iran, e-mail:ak.rahmanian@gmail.com.
FAU - Mohebali, Navideh
AU  - Mohebali N
FAU - Haghnegahdar, Ali
AU  - Haghnegahdar A
FAU - Kamali Sarvestani, Eskandar
AU  - Kamali Sarvestani E
FAU - Razmkon, Ali
AU  - Razmkon A
FAU - Kivelev, Juri
AU  - Kivelev J
FAU - Baghban, Fahim
AU  - Baghban F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Iran
TA  - Iran J Immunol
JT  - Iranian journal of immunology : IJI
JID - 101282932
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/*blood
MH  - Case-Control Studies
MH  - Chemokine CCL2/*blood
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Intracranial Aneurysm/complications/*diagnosis
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Subarachnoid Hemorrhage/complications/*diagnosis
EDAT- 2015/12/31 06:00
MHDA- 2016/10/01 06:00
CRDT- 2015/12/31 06:00
PHST- 2015/12/31 06:00 [entrez]
PHST- 2015/12/31 06:00 [pubmed]
PHST- 2016/10/01 06:00 [medline]
AID - 07 [pii]
PST - ppublish
SO  - Iran J Immunol. 2015 Dec;12(4):302-10.